Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials)

• Published in: The American journal of cardiology 2017-02, Vol.119 (3), p.397-403
• Main Authors: Mosca, Lori, MD, MPH, PhD, Ballantyne, Christie M., MD, Bays, Harold E., MD, Guyton, John R., MD, Philip, Sephy, RPh, PharmD, Doyle, Ralph T., BA, Juliano, Rebecca A., PhD
• Format: Article
• Language: English
• Subjects: 1-Alkyl-2-acetylglycerophosphocholine Esterase - blood; Aged; Apolipoprotein C-III - blood; Apolipoproteins; Apolipoproteins B - blood; C-Reactive Protein - metabolism; Cardiovascular; Cholesterol - blood; Cholesterol, HDL - blood; Cholesterol, LDL - blood; Cholesterol, VLDL - blood; Double-Blind Method; Eicosapentaenoic Acid - analogs & derivatives; Eicosapentaenoic Acid - therapeutic use; Female; Humans; Hypertriglyceridemia - blood; Hypertriglyceridemia - drug therapy; Lipoproteins, LDL - blood; Lipoproteins, VLDL - blood; Low density lipoprotein; Middle Aged; Statins; Studies; Treatment Outcome; Triglycerides - blood
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2016.10.027

There are limited data on the efficacy and safety of triglyceride (TG)-lowering agents in women. We conducted subgroup analyses of the effects of icosapent ethyl (a high-purity prescription form of the ethyl ester of the omega-3 fatty acid, eicosapentaenoic acid) on TG levels (primary efficacy variable) and other atherogenic and inflammatory parameters in a total of 215 women with a broad range of TG levels (200–2000 mg/dl) enrolled in two 12-week placebo-controlled trials: MARINE (n = 18; placebo, n = 18) and ANCHOR (n = 91; placebo, n = 88). Icosapent ethyl 4 g/day significantly reduced TG levels from baseline to week 12 versus placebo in both MARINE (−22.7%; p = 0.0327) and ANCHOR (−21.5%; p